Article Text

Download PDFPDF
Current and future directions in interventional neuro-oncology—are we there yet?
  1. Yang Qiao1,2,
  2. Maggie Xiong1,2,
  3. Yi Jonathan Zhang3,
  4. Samuel Tsappidi3,
  5. Peter Kan4,
  6. Clifford R Weiss5,6,
  7. Ferdinand Hui3,
  8. Stephen R Chen2
  1. 1Department of Diagnostic and Interventional Imaging, The University of Texas Health Science Center at Houston, Houston, Texas, USA
  2. 2Department of Interventional Radiology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA
  3. 3Department of Neurointerventional Surgery, The Queen's Health Systems, Honolulu, Hawaii, USA
  4. 4Neurosurgery, The University of Texas Medical Branch at Galveston, Galveston, Texas, USA
  5. 5Department of Radiology and Radiological Science, The Johns Hopkins University School of Medicine, Baltimore, Maryland, USA
  6. 6Department of Biomedical Engineering, Johns Hopkins University Whiting School of Engineering, Baltimore, Maryland, USA
  1. Correspondence to Dr Yang Qiao, Department of Diagnostic and Interventional Imaging, The University of Texas Health Science Center at Houston, Houston, TX 77030, USA; john.yang.qiao{at}


Advancements in technology and technical expertise increasingly enable neurointerventionalists to deliver safer and more effective endovascular treatments to cancers of the brain, spine, head, and neck. In addition to established neuro-oncological interventions such as pre-surgical tumor embolization and percutaneous ablation, newer modalities focused on direct arterial infusion of chemotherapy, radioisotopes, and radiosensitizers continue to gain traction as complementary treatment options, while stem cell-mediated delivery of theranostic nanoparticles and oncolytic virus are being explored for even greater specificity in targeting cancers across the blood–brain barrier. This article aims to provide an overview of the current state of the art and future directions for the field of interventional neuro-oncology, as well as opportunities and challenges presented by this emerging treatment modality.

  • Intervention
  • Malignant
  • Neoplasm
  • Technique
  • Tumor

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.


  • X @PeterKa80460001, @s0schen

  • Contributors YQ and MX contributed to writing, editing, and research. YJZ, ST, PK, CRW, FH, and SRC contributed to editing and clinical guidance. SRC contributed to angiographic, fundoscopic, and cross sectional imaging.

  • Funding The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.

  • Competing interests PK receives grants/contract funding from NIH, Siemens, Joe Niekro Foundation, and Medtronic; unrelated consulting fees from Stryker Neurovascular and Imperative Care; serves on the Editorial Board of the Journal of NeuroInterventional Surgery; and is an unrelated shareholder of Vena Medical. CRW receives grants/contract funding from Medtronic, Boston Scientific, Siemens, Guerbet, and NIH/NIDDK; consulting fees from Medtronic and Boston Scientific; serves as Vice Chair of the Society of Interventional Radiology; and has special interests with Avasys Medical and Shuriken Medical.

  • Provenance and peer review Not commissioned; externally peer reviewed.